Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: A multicentre prospective case series
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.06.001 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Sophie Gautier und 10 weiteren Autor:innen. Beteiligte Einrichtung: Regional Pharmacovigilance centre of Lille, CHU Lille, Univ. Lille, France. Electronic address: sophie.gautier@chu-lille.fr. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Chloride Channel Agonists, Abnormalities, Drug-Induced. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Assistance Publique - Hôpitaux de Paris, Foundation for Individual Rights in Education.
Abstract (Originalsprache)
BACKGROUND: Clinical data regarding in utero exposure to CFTR modulators (CFTRm) are limited. Our objective was to describe pregnancy outcomes, with particular attention to malformations, and neonatal adverse outcomes among prospective pregnancies exposed to CFTRm, using clinical data from the French Network of Pharmacovigilance Centres and the Teratology Information Service CRAT (Centre de Reference sur les Agents Tératogènes). METHODS: An observational multicentre study was performed on the reported CFTRm-exposed pregnancies with an expected delivery date between 2018 and 2023. We described prospective cases, defined as pregnancies for which the outcome was unknown and no adverse prenatal outcome was diagnosed at the time of first contact with the healthcare professional. Major congenital anomalies (MCA) were classified according to criteria of the European Registration of Congenital Anomalies and Twins. RESULTS: Fifty-eight pregnancies were included, mainly exposed to elezacaftor/tezacaftor/ivacaftor throughout pregnancy (87.9 %).There were 53 live births, four spontaneous abortions and one medical abortion (fetus with cystic fibrosis). One atrial septal defect and one acrania/anencephaly were observed, resulting in a MCA prevalence of 3.4 % (IC95 %: 0.4- 11.9). There were three neonatal adverse outcomes without a clearly identified cause: one sudden massive alveolar hemorrhage, one delayed respiratory distress and one delayed transient hypotonia. No cataract was found in children who had an ophthalmological examination (n = 10). CONCLUSIONS: This prospective case series - the largest to date - does not suggest a high rate of MCA or neonatal adverse outcomes in CFTRm-exposed pregnancies. Further studies including long-term follow-up of in utero exposed children are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Pharmacovigilance centre of Lille, CHU Lille, Univ. Lille, France. Electronic address: sophie.gautier@chu-lille.fr.
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Équipe PEPITES, AP-HP, Hôpital Pitié-Salpétrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (C…
- Centre Régional de Pharmacovigilance, CHU, Montpellier, Montpellier, France.
- Regional Center of Pharmacovigilance, Department of perinatal, pediatric and adult pharmacology, Hopital Cochin, Hopital Necker, AP-HP, Université Paris Cité, INSERM UMR 1343 « Pharmacologie et évaluation des thérapeuti…
- CHU Lille, Univ. Lille, CNRS, Inserm, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, Lille, France.
- AP‑HP.Sorbonne Université, Hôpital Pitié-Salpétrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), F75012, Paris, France.
Förderung
- Assistance Publique - Hôpitaux de Paris
- Foundation for Individual Rights in Education
Zitieren
APA
Gautier, S., Coulm, B., Thompson-Bos, M. A., Chouchana, L., Audousset, C., Elefant, E., Mankikian, J., Burgel, P. R., Garabedian, C., Marin, B., & Jonville-Bera, A. P. (2025). Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: A multicentre prospective case series. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.06.001
Vancouver
Gautier S, Coulm B, Thompson-Bos MA, Chouchana L, Audousset C, Elefant E, et al. Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: A multicentre prospective case series. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.06.001
BibTeX
@article{Gautier2025,
author = {Gautier, Sophie and Coulm, Bénédicte and Thompson-Bos, Marie-Andrée and Chouchana, Laurent and Audousset, Camille and Elefant, Elisabeth and Mankikian, Julie and Burgel, Pierre-Regis and Garabedian, Charles and Marin, Benoît and Jonville-Bera, Annie-Pierre},
title = {Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: A multicentre prospective case series},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.06.001}
}
EUVIMED